Unitat de Recerca en Lípids i Arteriosclerosi, CIBERDEM, Hospital Universitari Sant Joan de Reus, IISPV, Universitat Rovira i Virgili, Reus, Spain.
PLoS One. 2012;7(2):e31103. doi: 10.1371/journal.pone.0031103. Epub 2012 Feb 27.
Cocoa, mixed with other food ingredients, intake can have beneficial effects on cardiovascular disease (CVD) biomarkers. We compared the effects of 4 cocoa cream products on some of these biomarkers.
In this multi-centered, randomized, controlled, double-blind, parallel trial, volunteers (n = 113; age range: 43-65 years) who were pre-hypertensive, stage-1 hypertensive and hypercholesterolemic received one of 4 cocoa cream products (13 g/unit; 1 g cocoa/unit, 6 units/d; 465 Kcal/d) added to a low saturated fat diet for 4 weeks. The groups were: A) (n = 28), cocoa cream considered as control; B) (n = 28), cocoa+hazelnut cream (30 g/d hazelnuts); C) (n = 30), cocoa+hazelnuts+phytosterols (2 g/d); and D) (n = 27), cocoa+hazelnuts+phytosterols+soluble fiber (20 g/d) the patented "LMN product". Primary outcome measures were BP, LDL-c, apolipoprotein B-100 (Apo B), ApoB/ApoA ratio, oxidized LDL (oxLDL) and high-sensitive C-reactive protein (hsCRP) determined at baseline and post-cocoa cream product intake. Statistical analysis used was ANCOVA or mixed models (in case of repeated measurements), with baseline observation included as a covariate. After 4 weeks, compared to product A, product C reduced LDL-c by 11.2%, Apo B by 8.1% and ApoB/ApoA ratio by 7.8% (P = 0.01). LMN decreased LDL-c by 9.2%, Apo B-100 by 8.5%, ApoB/ApoA ratio by 10.5%, hsCRP by 33.4% and oxLDL by 5.9% (P = 0.01). Surprisingly, even "control" product A reduced systolic BP (-7.89 mmHg; 95%CI: -11.45 to -4.3) and diastolic BP (-5.54 mmHg; 95%CI: -7.79 to -3.29). The BP reductions were similar with the other 3 products. Limitations of the study are that the trial period was relatively short and that a better "BP control" product would have been preferable.
The creams (particularly the LMN) have anti-inflammatory and antioxidant effects in addition to lowering LDL-c, Apo B and ApoB/ApoA ratio. Thus, the soluble fiber effects amplified with sterols (as contained in the cocoa creams) provide new dietary therapeutic perspectives.
Clinicaltrials.gov NCT00511420.
可可与其他食物成分混合摄入,可能对心血管疾病(CVD)生物标志物产生有益影响。我们比较了 4 种可可奶油产品对其中一些生物标志物的影响。
在这项多中心、随机、对照、双盲、平行试验中,患有高血压前期、1 期高血压和高胆固醇血症的志愿者(n=113;年龄范围:43-65 岁)接受了 4 种可可奶油产品(每单位 13 克;每单位 1 克可可,每天 6 份;每天 465 卡路里)中的一种添加到低饱和脂肪饮食中,持续 4 周。组分为:A)(n=28),可可奶油被认为是对照;B)(n=28),可可+榛子奶油(每天 30 克榛子);C)(n=30),可可+榛子+植物固醇(每天 2 克);和 D)(n=27),可可+榛子+植物固醇+可溶性纤维(每天 20 克)专利的“LMN 产品”。主要观察指标为血压(BP)、低密度脂蛋白胆固醇(LDL-c)、载脂蛋白 B-100(Apo B)、ApoB/ApoA 比值、氧化型低密度脂蛋白(oxLDL)和高敏 C 反应蛋白(hsCRP),在基线和摄入可可奶油产品后测定。使用协方差分析或混合模型(在重复测量的情况下)进行统计分析,将基线观察值作为协变量。4 周后,与产品 A 相比,产品 C 降低了 11.2%的 LDL-c、8.1%的 Apo B 和 7.8%的 ApoB/ApoA 比值(P=0.01)。LMN 降低了 9.2%的 LDL-c、8.5%的 Apo B-100、10.5%的 ApoB/ApoA 比值、33.4%的 hsCRP 和 5.9%的 oxLDL(P=0.01)。令人惊讶的是,即使是“对照”产品 A 也降低了收缩压(-7.89mmHg;95%CI:-11.45 至-4.3)和舒张压(-5.54mmHg;95%CI:-7.79 至-3.29)。其他 3 种产品的降压效果相似。本研究的局限性在于试验期相对较短,更好的“血压控制”产品可能会更好。
除了降低 LDL-c、Apo B 和 ApoB/ApoA 比值外,奶油(特别是 LMN)还具有抗炎和抗氧化作用。因此,含有固醇(如可可奶油中所含)的可溶性纤维的作用放大,为新的饮食治疗提供了新的视角。
Clinicaltrials.gov NCT00511420。